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O-glycoprotein 2-acetamino-2-deoxy-β-D-glucopyranosidase (O-GlcNAcase) 
hydrolyzes 2-acetamido-2-deoxy-β-D-glucopyranose (O-GlcNAc) residues of serine/threonine 
residues of modified proteins. O-GlcNAc is present in many intracellular proteins and appears 
to have a role in the etiology of several diseases including cancer, Alzheimer’s disease, and 
type II diabetes. In this work, we have carried out molecular dynamics (MD) simulations 
using a hybrid Quantum Mechanics / Molecular Mechanics (QM/MM) approach, to determine 
the binding of two potent inhibitors, PUGNAc and NAG, with a bacterial O-GlcNAcase. The 
results of these simulations show that Asp-401, Asp-298 and Asp-297 residues play an 
important role in the protein-inhibitor interactions. These results might be useful to design 
compounds with more interesting inhibitory activity on the basis of its three-dimensional 
structure. 
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3 
Introduction 
 
O-glycoprotein 2-acetamino-2-deoxy-β-D-glucopyranosidase (O-GlcNAcase) is a 
member of the family of glycoside hydrolases-84 (GH84)1 that hydrolyzes 2-acetamido-2-
deoxy-β-D-glucopyranose (O-GlcNAc) residues from posttranslationally modified 
serine/threonine residues of nucleocytoplasmic protein.1-3 O-GlcNAc is abundant in the brain, 
particularly on cytoskeletal proteins,4-5 which has supported hypothesis that disruptions of O-
GlcNAc proteins may contribute to certain neurodegenerative disorders such as Parkinson 
dystonia6 and Alzheimer’s disease.5 O-GlcNAc is also present in many transcription 
regulatory proteins. Mutations of many of these proteins contribute to the oncogenic 
phenotype. Some of these mutations may exert their effects in part by interference of O-
GlcNAc-mediated regulation of these proteins. In this regard, recent studies have clearly 
established that the conversion of glucose into glucosamine, which is catalyzed by glutamine, 
is essential for the development of insulin resistance, drawing a link between O-GlcNAc 
misregulation and type II diabetes.7-8 
O-GlcNAcase catalyzed reaction takes place through a two-step mechanism, forming a 
transient oxazoline intermediate (see structure 3 in Figure 1) that it is subsequently broken. 
Oxazoline formation is a substrate-assisted process, where the 2-acetomido group is activated 
by an Asp residue, while departure of the aglycone leaving group is assisted by means of  a 
proton transfer from a protonated Asp (see the hypothetical transition structure 2 in Figure 1). 
Inhibitors of O-GlcNAcase activity have been developed trying to mimic the geometrical 
and/or electronic properties of structures appearing during the reaction process, either 
transition structures or intermediates. O-(2-acetamido-2-deoxy-D-
glucopyranosylidene)amino-N-phenylcarbamate (PUGNAc, 4) and 1,2-dideoxy-2’-methyl-α-
D-glucopyranoso-[2,1-d]-Δ2’-thiazoline (NAG-thiazoline, 5) are potent and the best 
characterized inhibitors of human O-GlcNAcase.9 Recently, the crystal structure of a bacterial 
Clostridium perfringens homologue (CpGH84H) in complex with PUGNAc was reported, 
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with significant sequence homology to the human O-GlcNAcase.10 Moreover, similarities 
between the inhibition constants of human O-GlcNAcase and CpGH84H were observed, 
making this bacterial enzyme a good model of the human enzyme.10 The analysis of enzyme-
PUGNAc complex suggests that this molecule inhibits O-GlcNAcase by mimicking the 
transition state of the O-GlcNAcase-catalyzed hydrolysis of N-acetylglucosaminide by virtue 
of its sp2 anomeric C1, similar to the oxocarbenium ion-like transition state.10 On the other 
hand NAG-thiazoline is, in principle, geometrically similar to the oxazoline intermediate. 
More recently, Whitworth and co-workers have shown that NAG-thiazoline is a transition 
state analogue for O-GlcNAcase, while PUGNAc is a poor transition state analogue.11  
The aim of this work is to understand the molecular mechanism by which such 
molecules inhibit the catalytic activity of its target enzyme, which will be useful for designing 
potent inhibitors of O-GlcNAcase. Recently, we have successfully used molecular dynamics 
(MD) simulations, using a combined quantum mechanical/molecular mechanical (QM/MM) 
approach,13-15 to study the relationship between protein-ligand interaction potential energies 
and HIV-1 IN inhibitor activity.12 In the present work, electrostatic binding free energy of 
CpGH84H complexed with both PUGNAc and NAG-thiazoline have been computed. 
Nevertheless, the problem of the protonation state of the inhibitors and the ionisable key 
aminoacids of the enzyme active site has to be sort out in advance. Thus, as shown in Figure 
1, two proton transfer process occur between the substrate and the enzyme (Asp-297 and Asp-
298 in CpGH84H) and these can be more or less advanced in the transition state of the 
reaction. Correct molecular modelling of the inhibitors should consider different positioning 
of these protons either on the inhibitor or the enzyme side. Finally, a detailed analysis of the 
interactions of the two inhibitors mentioned above with the key residues inside the binding 
pocket has been carried out in order to understand the differences between these two families 
of inhibitors.  
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Computational Methods 
The initial coordinates for the QM/MM MD calculations were taken from the trimeric 
crystal structure of CpGH84H-PUGNAc complex, with PDB code 2CBJ.10 This structure has 
been also used as a starting point for NAG-thiazoline inhibitor, by changing the PUGNAc 
substrate molecule by the NAG-thiazoline. Since standard pKa values of ionizable groups can 
be shifted by local protein environments,16 an accurate assignment of the protonation states of 
all these residues at pH=7 was carried out by recalculating the standard pKa values of the 
titratable amino acids using the “cluster method”,17 as implemented by Field and co-
workers.16b According to this method, each titratable residue in the protein is perturbed by the 
electrostatic effect of the protein environment. We have also performed calculation of pKa 
values of aminoacids within the empirical propKa program of Jensen et al.18 Results obtained 
with both methods are qualitatively in agreement, predicting the same protonation state for all 
residues at the selected pH of the simulations (see Supporting Information). Thus, according 
to these results, most residues were found at their standard protonation state, except Asp-298 
residue that seems to be protonated at this pH. Interestingly, Asp-298 has been proposed to be 
the catalytic acid, protonating the glycosidic bond in the first step of the O-GlcNAcase-
catalyzed hydrolysis of N-acetylglucosaminides, while Asp-297 would be a general base in a 
typical acid/base catalysis.19 Therefore, in this work we have modelled the PUGNAc-enzyme 
complex protonating the Asp-298 (A form in Figure 2) or protonating the oxime nitrogen of 
PUGNAc (B form in Figure 2). This latter complex, B, would resemble a more advanced 
stage of the reaction process, with the leaving group being protonated. On the other side, in 
order to model NAG-thiazoline-enzyme complex, we must keep in mind that the pKa of the 
nitrogen atom at C2 position of the substrate is expected to change during the reaction, 
reaching in the intermediate state a value close to that of aspartate.19 A strong hydrogen bond 
is then expected to be found between these two moieties. Thus, we modelled the enzyme-
inhibitor complex protonating Asp-298 and Asp-297 (C form in Figure 2) or protonating Asp-
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298 and the nitrogen of thiazoline ring of the NAG-thiazoline (D form in Figure 2). Finally, 
for comparative purposes, we also considered an enzyme-inhibitor complex protonating only 
Asp-298, while no proton was considered either in the C2 nitrogen atom or in Asp-297 (E 
form in Figure 2).  
After adding the hydrogen atoms to the structure, series of optimization algorithms 
(steepest descent conjugated gradient and L-BFGS-B20) were applied. In order to avoid a 
denaturalization of the protein structure, all the heavy atoms of the protein and the inhibitor 
were restrained by means of a Cartesian harmonic umbrella with a force constant of  1000 
kJ·mol-1·Å-2. Afterwards the system was fully relaxed, but restraining the peptidic backbone 
with a lower constant of 100 kJ·mol-1·Å-2. 
 Then the optimized protein was placed in a cubic box of pre-equilibrated water 
molecules (80 Å side), using the principal axis of the protein-inhibitor complex as the 
geometrical center. Any water with an oxygen atom lying in a radius of 2.8 Å from a heavy 
atom of the protein was deleted. The remaining water molecules were then relaxed using 
optimization algorithms. Afterwards, 100 ps of hybrid QM/MM Langevin-Verlet molecular 
dynamics (MD) at 300K and in a canonical thermodynamic ensemble (NVT) were used to 
equilibrate de model. For the hybrid QM/MM MD calculations, only the atoms of the 
inhibitor were selected to be treated by QM, using a semiempirial AM1 hamiltonian.21 The 
rest of the system (protein plus water molecules) were described using the OPLS-AA22 and 
TIP3P23 force fields, respectively, as implemented in the DYNAMO library.24 
Due to the amount of degrees of freedom, any residue 20 Å apart from any of the 
atoms of the initial inhibitor was selected to be kept frozen in the remaining calculations. 
Cutoffs for the non-bonding interactions were applied using a switching scheme, within a 
range radius from 14.5 to 16 Å.  
Once the system was pre-equilibrated, 1500ps of QM/MM MD were run at 
temperature of 300 K for each system. The computed RMSD for the protein during the last 
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400 ps renders a value always below 0.9 Å, while the RMS of the temperature along the 
different equilibration steps was always lower than 2.5 K and the variation coefficient of the 
potential energy during the dynamics simulations was never higher than 0.3%. 
Finally, QM/MM optimizations were carried out from structures derived from the 
AM1/MM MD simulations, using AM1 hamiltonian and B3LYP functional25 together with 
the 6-31G* basis set, to describe the QM region of the system.  
The potential energy of our scheme is derived from the standard QM/MM formulation: 
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where MME  is the energy of the MM subsystem terms, 
vdW
MMQME /  the van der Waals interaction 
energy between the QM and MM subsystems and 
elect
MMQME /  includes both the coulombic 
interaction of the QM nuclei ( QMZ ) and the electrostatic interaction of the polarized electronic 
wave-function (Ψ ) with the charges of the protein ( MMq ). In order to take advantage of 
powerful optimizations algorithms (see for example ref 26), we have substituted the 
electrostatic interaction term by a pure coulombic one, in which the charges of the QM atoms 
are obtained by means of electrostatic potential fit methods based on the electronic density.27 
Thus the final potential energy can be approximated by: 
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The interaction energy between the inhibitor and the environment, computed by residue, is 
evaluated as the difference between the QM/MM energy and the energies of the separated, 
non-interacting, QM and MM subsystems with the same geometry. Considering that the MM 
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part is described using a non-polarizable potential the interaction energy contribution of each 
residue of the protein is given by the following expression: 
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Equation 4 is valid since the polarization effect cannot be decomposed in individual 
contributions. The global polarization effect can be obtained from the gas phase energy 
difference between the polarized, Ψ , and unpolarized, oΨ , wave functions. 
Finally, in order to evaluate the electrostatic binding free energy, series of QM/MM MD 
simulations have been carried out, introducing a λ parameter in the electrostatic QM/MM 
interaction: 
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Then λ smoothly changes between values of 1, corresponding to a full MM charge-wave 
function interaction, and 0 whereas no electrostatic interaction with the force field is 
introduced. Note that the van der Waals interaction is always calculated. 
The calculation of the free energy difference of two consecutive windows is performed by 
means of free energy perturbation (FEP) methods, which for the case of non-polarizable 
classical force fields reduces to: 
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We have used a total of 100 windows, from λ=0 (no electrostatic interaction) to λ=1 (full 
interaction), which turns into a δλ of 0.01. The total free energy term is then evaluated as the 
sum of all the windows.  The procedure can be applied both forwards (i→i+1) and backwards 
(i+1→i) as long as the comparison provides information about the convergence of the 
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process. In each window a total of 5 ps of relaxation followed by 10 ps of production 
QM/MM MD have been performed. Since the use of high level Hamiltonians for performing 
hybrid MD is actually prohibitive, the electrostatic free energy has been evaluated using the 
semiempirical AM1 hamiltoninan. 
 
Results and Discussion 
Figure 2 shows the B3LYP/MM optimized structures obtained from the 1.5 ns 
AM1/MM MD simulations, while the contribution of individual residues to the total protein-
substrate interaction energy is displayed in Figure 3. In this later figure, negative values 
correspond to stabilizing effects. From Figure 2 it can be shown that the principal structural 
difference between forms A and B in PUGNAc-enzyme complex is found in the orientation of 
residue Asp-298. In A form the exocyclic oxime nitrogen of PUGNAc interacts through 
hydrogen bond with Tyr-335 residue, while in B this substrate atom is forming a hydrogen 
bond with Asp-298 residue. X-ray crystallographic data10 is, in general, very close to structure 
B, although the exocyclic oxime nitrogen of PUGNAc forms two hydrogen bonds with both 
Asp-298 and Tyr-335 residues in the experimentally determined structure. The strong 
interaction with Asp-298 residue favor the stabilization of the protein-inhibitor complex as 
can be observed in Figure 3, in accordance with the observation that the protonated nitrogen 
engaged in an adventitious electrostatic interaction with the general acid/base catalytic 
residue.28 Furthermore, it was found that mutation of Asp298 to Asn reduces kcat of enzyme 
catalyzed reaction by 8100-fold.10 Other important residues are Asp-297 and Asp-401. Asp-
297 presents hydrogen bond interactions with nitrogen of amide nitrogen, being this 
interaction responsible of stabilizing the conformation of acetamido group and, as observed in 
Figure 3, presenting a favourable interaction with the ligand. Regarding Asp-401, it presents 
favourable interactions with O4 and O6 hydroxyl oxygen atoms of the ligand. Interestingly, it 
is observed that mutation of Asp-401 has significant effects on both, the ability of the enzyme 
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to bind the inhibitor and catalysis (10-fold increase in Km and reduces kcat 2400-fold).10 
Tyr335, Trp394 and Trp490 seem to be stabilizing the cavity created by the three 
aforementioned residues. Finally, due to the change of substrate charge between both 
complexes, Lys184’ (a residue belonging to a different protein chain) presents a 
electrostatically favourable interaction with the substrate in A complex, while it is 
unfavourable in B.  
Regarding the NAG-thiazoline inhibitor, C, D and E complexes can be compared with 
previously experimentally determined Bacteroides thetaiotaomicron GH84 (BtGH84)29 
structure bound to a derivative of this inhibitor. Thus, X-ray crystallographic data10 show that 
Asp-297 (Asp-242 in BtGH84) is positioned to form a hydrogen bond with the nitrogen of the 
thiazoline ring of the inhibitor, in accordance with D structure. In general, this complex is the 
closest one to the crystallographic structure and, therefore, only this structure will be 
discussed in this paper. Notably, PUGNAc and NAG-thiazoline pattern of interactions within 
the CpGH84H active site are very similar (compare B and D in Figure 3). Differences are 
observed in their interactions with Asp-297 and Asp298. While PUGNAc, in its B form, 
interacts strongly through Asp-298, NAG-thiazoline presents a larger stabilizing interaction 
with Asp-297 in the D form. These differences are consequence of the different pKa’s of the 
inhibitors. While oxime nitrogen atom of PUGNAc is able to accept a proton from Asp-298 
and thus to establish a salt bridge with the protein, the smaller value of the pKa of the 2-
nitrogen atom in NAG-thiazoline makes the hydrogen bond with unprotonated Asp-297 
stronger in this last case while Asp298 remains protonated. This result is in accordance with 
studies of Whitworth and co-workers, who reported a comparative study of substrate-inhibitor 
hydrogen bond interactions concluding that interactions between residues with closely 
matched pKa values are stronger than those between residues whose pKa values differ 
greatly.11 Finally, last residue establishing a strong interaction with both inhibitors is Asp-
401, that presents a similar orientation to the one observed in the BtGH84 crystal structure.29b 
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The comparison of three-dimensional molecular electrostatic potential (MEP) surfaces for 
compounds depicted in Figure 2 is depicted in Figure 4. MEPs surfaces were generated, with 
Gauss View program,30 from the B3LYP/MM optimized structures. These surfaces 
correspond to an isodensity value of 0.002 a.u. The most nucleophilic regions (negative 
electronic potential) are shown in red, while and the most electrophilic regions (positive 
electrostatic potential) are shown in blue. The similarity of the MEP calculated for both 
inhibitors in their correct protonation states (B and D forms) is evident. Both cases display a 
large positive (blue) regions matching with the positions of Asp-297, Asp-298 and Asp-401. 
It is interesting to note that these positive potentials are a consequence either of the inhibitor 
itself (the NAG-thiazoline case) or as a consequence of a proton transfer from the protein 
(PUGNAc). These MEPs can be then used as templates for the design of new potent 
inhibitors. In addition this analysis can be used to get some clues about the transition state of 
the catalyzed reaction. One could conclude that in this transition state the proton transfer from 
Asp-298 should be completed while the transfer to Asp-297 is most probably in a much 
earlier stage. The principal difference between the two most efficient inhibitors, B and D, is in 
phenyl carbamate moiety, which is absent in NAG-thiazoline. 
Electrostatic binding free energies obtained from the FEP calculations at the 
AM1/MM level are shown in Table 1, Analysis of the results reveals that NAG-thiazoline-
enzyme B complex has a binding free energy which is close to the value calculated for the 
PUGNAc-enzyme D complex. The small difference observed between these two inhibitors 
(19 kJ/mol) is in agreement with the experimental, i. e., PUGNAc binds only 0.66-fold more 
tightly than NAG-thiazoline in human O-GlcNAcase.9 The loss of ligand-protein interaction, 
mainly trough Asp-298 residue in NAG-thiazoline complex, may be responsible for the 
differences in the activity between these inhibitors. By comparison of calculated binding free 
energies and the experimental measurements of KI, it can be observed a direct relationship 
between both properties, which could be used as a guide in the design of new inhibitors.  
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In summary, our results suggest that design of an effective inhibitor should resemble the TS 
of the enzyme catalyzed reaction and theoretical calculations can be used to guide its 
synthesis. 
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Table 1: Binding free energies ( MMQMElectF /−Δ ) obtained from the electrostatic FEP 
calculations at the AM1/MM level (in kJ·mol-1). Experimental ligand-protein dissociation 
constants (KI in μM, from ref 9) are reported for comparisons purposes. 
 
Ligand MMQMElectF /−Δ  KI 
B -348.4 0.07 
D -367.4 0.046 
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Figure captions: 
 
Fig. 1: Schematic representation of the first reaction step in O-GlcNAcase from 
reactants (1) to the oxazoline intermediate (3) through an hypothetical transition 
state (2). Structures of PUGNAc (4) and NAG-thiazoline (5) inhibitors are also 
shown. Numbering of residues corresponds to bacteria Clostridium perfringens. 
 
Fig. 2: B3LYP/MM optimized structures obtained after 1.5 ns of AM1/MM MD 
simulations for the following O-GlcNAcase-inhibitor structures: (A) PUGNAc-
enzyme, protonating Asp-298 (B) PUGNAc-enzyme, protonating the oxime 
nitrogen of PUGNAc; (C) NAG-thiazoline-enzyme, protonating Asp-297 and 
Asp-298; (D) NAG-thiazoline-enzyme, protonating Asp-298 and the nitrogen of 
thiazoline ring of the NAG-thiazoline; (E) NAG-thiazoline-enzyme, protonating 
the Asp-298. Selected hydrogen bond distances in Angstroms. 
 
Fig. 3: Contributions of individual amino acid residues to inhibitor binding energy (in 
kcal·mol-1) computed for the B3LYP/MM optimized structures obtained after 1.5 
ns of AM1/MM MD simulations for the different O-GlcNAcase-inhibitor 
structures depicted in Figure 1. 
 
Fig. 4: Electrostatic potential (MEP) surfaces derived from BLYP/6-31G*/MM 
calculations for the compounds shown in Figure 1. The increase of negative 
charges goes from the blue (positive) to red (negative). 
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